Streaming now on: Amazon Music | Apple Podcasts | Spotify | Soundcloud | YouTube
Learn More About Beyond the Endpoint | View All Episodes
In the second episode of our three-part series on obesity, hosts Manesh Patel and Emily O'Brien discuss GLP-1 receptor agonist medications with Neha Pagidipati, a preventive cardiologist. More commonly known by brand names like Ozempic and Mounjaro, these therapies are transforming the treatment of diabetes, cardiovascular disease, and obesity. Ongoing research suggests that their use may even extend beyond these conditions. This episode explores the scientific and clinical implications of GLP-1s, shedding light on access challenges, patient experiences, and the complex journey of understanding one of medicine's most exciting current frontiers.
About Our Guest
Neha J. Pagidipati, MD, MPH, is an Associate Professor of Medicine and cardiometabolic disease prevention specialist at the Duke Clinical Research Institute. She has been involved with cardiometabolic disease prevention research since 2011. Currently, her research focuses on clinical trials and the implementation of evidence-based care of patients with high cardiovascular disease risk and lipid disorders, hypertension, diabetes, and/or obesity. Clinically, she directs the Duke Cardiometabolic Prevention Program, which focuses on behavior change and risk factor management in patients at high risk of cardiovascular and metabolic diseases.
Learn More About Neha Pagidipati